المؤلفون: Li, Chenshuang, Zheng, Zhong, Ha, Pin, Jiang, Wenlu, Berthiaume, Emily A, Lee, Seungjun, Mills, Zane, Pan, Hsinchuan, Chen, Eric C, Jiang, Jie, Culiat, Cymbeline T, Zhang, Xinli, Ting, Kang, Soo, Chia

مصطلحات موضوعية: Control Engineering, Mechatronics and Robotics, Engineering, Biomedical Engineering, Osteoarthritis, Pain Research, Chronic Pain, Aging, Arthritis, 2.1 Biological and endogenous factors, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Aetiology, Inflammatory and immune system, Musculoskeletal, Animals, Anti-Inflammatory Agents, Calcium-Binding Proteins, Cartilage, Articular, Chondrocytes, Chondrogenesis, Interleukin-1beta, Mice, Pharmaceutical Preparations, Cartilage damage, Disease-modifying osteoarthritis drug, Inflammation, Neural EGFL like 1, Runt-related transcription factor 1

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/1bs3j04mTest
https://escholarship.org/content/qt1bs3j04m/qt1bs3j04m.pdfTest

المؤلفون: Gyeong Min Kim, Doo Ri Park, Thi Thu Ha Nguyen, Jiseon Kim, Jihee Kim, Myung-Ho Sohn, Won-Kyu Lee, Soo Young Lee, Hyunbo Shim

المصدر: Biomedicines, Vol 11, Iss 10, p 2844 (2023)

مصطلحات موضوعية: OSCAR, osteoarthritis, human antibody, chondrocyte, disease-modifying osteoarthritis drugs, DMOAD, Biology (General), QH301-705.5

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2227-9059/11/10/2844Test; https://doaj.org/toc/2227-9059Test

الوصول الحر: https://doaj.org/article/5b2e284499bd4a42b5680439ca38020aTest

المؤلفون: Guermazi, A. (Ali), Roemer, F. W. (Frank W.), Crema, M. D. (Michel D.), Jarraya, M. (Mohamed), Mobasheri, A. (Ali), Hayashi, D. (Daichi)

مصطلحات موضوعية: MRI, clinical trial, disease-modifying osteoarthritis drugs, imaging, knee osteoarthritis

وصف الملف: application/pdf

الإتاحة: http://urn.fi/urn:nbn:fi-fe20230928137736Test

المؤلفون: O. A. Shavlovskaya, О. А. Gromova, A. Yu. Kochish, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova, О. А. Шавловская, О. А. Громова, А. Ю. Кочиш, Ю. Д. Юхновская, И. Д. Романов, И. А. Бокова

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 16, No 3 (2023); 482-499 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 16, No 3 (2023); 482-499 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: неденатурированный коллаген II типа, osteoarthritis immunology, disease-modifying osteoarthritis drugs, DMOADs, chondroitin sulfate, glucosamine sulfate, undenatured type II collagen, иммунология остеоартрита, болезнь-модифицирующие остеоартрит препараты, хондроитина сульфат, глюкозамина сульфат

وصف الملف: application/pdf

العلاقة: https://www.pharmacoeconomics.ru/jour/article/view/874/495Test; Oo W.M., Little C., Hunter D.J. The development of disease-modifying therapies for osteoarthritis (DMOADS): the evidence to date. Drug Des Devel Ther. 2021; 15: 2921–45. https://doi.org/10.2147/DDDT.S295224Test.; Oo W.M., Hunter D.J. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Ther Adv Musculoskel Dis. 2022; 14: 1759720X221090297. https://doi.org/10.1177/1759720X221090297Test.; Oo W.M., Hunter D.J. Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019; 37 (Suppl. 120 (5)): 135–40.; Guermazi A., Roemer F.W., Crema M.D., et al. Strategic application of imaging in DMOAD clinical trials: focus on eligibility, drug delivery, and semiquantitative assessment of structural progression. Ther Adv Musculoskelet Dis. 2023; 15: 1759720X231165558. https://doi.org/10.1177/1759720X231165558Test.; Skiöldebrand E., Adepu S., Lützelschwab C., et al. A randomized, triple-blinded controlled clinical study with a novel disease-modifying drug combination in equine lameness-associated osteoarthritis. Osteoarthr Cartil Open. 2023; 5 (3): 100381. https://doi.org/10.1016/j.ocarto.2023.100381Test.; Fan Y., Li Z., He Y. Exosomes in the pathogenesis, progression, and treatment of osteoarthritis. Bioengineering. 2022; 9: 99. https://doi.org/10.3390/bioengineering9030099Test.; Makarczyk M.J., Gao Q., He Y., et al. Current models for development of disease-modifying osteoarthritis drugs. Tissue Eng Part C Methods. 2021; 27 (2): 124–38. https://doi.org/10.1089/ten.TEC.2020.0309Test.; Rodriguez-Merchan E.C. The current role of disease-modifying osteoarthritis drugs. Arch Bone Jt Surg. 2023; 11 (1): 11–22. https://doi.org/10.22038/ABJS.2021.56530.2807Test.; Brent J.M., Tian Z., Yao L., et al. Functional deficits in mice expressing human interleukin 8. Comp Med. 2020; 70 (3): 205–15. https://doi.org/10.30802/AALAS-CM-19-000049Test.; Zhang Y., Chee A., Shi P., et al. Allogeneic articular chondrocyte transplantation down regulates interleukin 8 gene expression in the degenerating rabbit intervertebral disk in vivo. Am J Phys Med Rehabil. 2015; 94: 530–8. https://doi.org/10.1097/PHM.0000000000000194Test.; Chen S., Chen W., Chen Y., et al. Chondroitin sulfate modified 3D porous electrospun nanofiber scaffolds promote cartilage regeneration. Mater Sci Eng C Mater Biol Appl. 2021; 118: 111312. https://doi.org/10.1016/j.msec.2020.111312Test.; Corradetti B., Taraballi F., Minardi S., et al. Chondroitin sulfate immobilized on a biomimetic scaffold modulates inflammation while driving chondrogenesis. Stem Cells Transl Med. 2016; 5: 670–82. https://doi.org/10.5966/sctm.2015-0233Test.; Huanga H., Loua Z., Zhenga S., et al. Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage. Drug Delivery. 2022; 29 (1): 767–91. https://doi.org/10.1080/10717544.2022.2048130Test.; Wang J., Wang X., Cao Y., et al. Therapeutic potential of hyaluronic acid/chitosan nanoparticles for the delivery of curcuminoid in knee osteoarthritis and an in vitro evaluation in chondrocytes. Int J Mol Med. 2018; 42: 2604–14. https://doi.org/10.3892/ijmm.2018.3817Test.; Gencoglu H., Orhan C., Sahin E., Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals (Basel). 2020; 10 (4): 697. https://doi.org/10.3390/ani10040697Test.; Makarczyk M.J., Hines S., Yagi H., et al. Using microphysiological system for the development of treatments for joint inflammation and associated cartilage loss – a pilot study. Biomolecules. 2023; 13: 384. https://doi.org/10.3390/biom13020384Test.; Fernandes T.L., Gomoll A.H., Lattermann C., et al. Macrophage: a potential target on cartilage regeneration. Front Immunol. 2020; 11: 111. https://doi.org/10.3389/fimmu.2020.00111Test.; Griffin T.M., Scanzello C.R. Innate inflammation and synovial macrophages in osteoarthritis pathophysiology. Clin Exp Rheumatol. 2019; 37 (Suppl. 120): 57–63.; Nedunchezhiyan U., Varughese I., Sun A.R., et al. Obesity, inflammation, and immune system in osteoarthritis. Front Immunol. 2022; 13: 907750. https://doi.org/10.3389/fimmu.2022.907750Test.; Wang W., Chu Y., Zhang P., et al. Targeting macrophage polarization as a promising therapeutic strategy for the treatment of osteoarthritis. Int Immunopharmacol. 2023; 116: 109790. https://doi.org/10.1016/j.intimp.2023.109790Test.; Mantovani A., Sica A., Sozzani S., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25 (12): 677–86. https://doi.org/10.1016/j.it.2004.09.015Test.; Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci. 2008; 1 (13): 453–61. https://doi.org/10.2741/2692Test.; Dai M., Sui B., Xue Y., et al. Cartilage repair in degenerative osteoarthritis mediated by squid type II collagen via immunomodulating activation of M2 macrophages, inhibiting apoptosis and hypertrophy of chondrocytes. Biomaterials. 2018; 180: 91–103. https://doi.org/10.1016/j.biomaterials.2018.07.011Test.; Lepage S.I.M., Robson N., Gilmore H., et al. Beyond cartilage repair: the role of the osteochondral unit in joint health and disease. Tissue Eng Part B Rev. 2019; 25: 114–25. https://doi.org/10.1089/ten.teb.2018.0122Test.; Торшин И.Ю., Громова О.А., Лила А.М. и др. Толл-подобные рецепторы как компонент патофизиологии остеоартрита: противовоспалительное, анальгетическое и нейропротекторное действие. Неврология, нейропсихиатрия, психосоматика. 2021; 13 (4): 123–9. https://doi.org/10.14412/2074-2711-2021-4-123-129Test.; Miller R.E., Scanzello C.R., Malfait A.M. An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. Semin Immunopathol. 2019; 41 (5): 583–94. https://doi.org/10.1007/s00281-019-00762-3Test.; Li Y.S., Luo W., Zhu S.A., Lei G.H. T-cells in osteoarthritis: alterations and beyond. Front Immunol. 2017; 8: 356. https://doi.org/10.3389/fimmu.2017.00356Test.; Громова О.А., Торшин И.Ю., Лила А.М., Шавловская О.А. О перспективах использования неденатурированного коллагена II типа в терапии остеоартрита и других заболеваний суставов. Современная ревматология. 2022; 16 (4): 111–6. https://doi.org/10.14412/1996-7012-2022-4-111-116Test.; Шавловская О.А., Юхновская Ю.Д., Романов И.Д., Бокова И.А. Фармаконутрицевтик Хондрогард® ТРИО – хондропротектор, обладающий иммуномодулирующим действием. Неврология, нейропсихиатрия, психосоматика. 2023; 15 (4): 105–11. https://doi.org/10.14412/2074-2711-2023-4-105-111Test.; Uebelhoer M., Lambert C., Grisart J., et al. Interleukins, growth factors, and transcription factors are key targets for gene therapy in osteoarthritis: a scoping review. Front Med. 2023; 10: 1148623. https://doi.org/10.3389/fmed.2023.1148623Test.; Roman-Blas J.A., Castañeda S., Sánchez-Pernaute O., et al. Chondroitin sulfate plus glucosamine sulfate shows no superiority over placebo in a randomized, double-blind, placebo-controlled clinical trial in patients with knee osteoarthritis. Arthritis Rheumatol. 2017; 69 (1): 77–85. https://doi.org/10.1002/art.39819Test.; Reginster J.V., Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2021; 33 (1): 37–47. https://doi.org/10.1007/s40520-020-01643-8Test.; Ozeki N., Koga H., Nakagawa Y., et al. Association between knee cartilage thickness determined by magnetic resonance imaging three-dimensional analysis and the International Cartilage Repair Society (ICRS) arthroscopic grade. Knee. 2023; 42: 90–8. https://doi.org/10.1016/j.knee.2023.02.005Test.; Li X., Roemer F.W., Flavia Cicuttini F., et al. Early knee OA definition-what do we know at this stage? An imaging perspective. Ther Adv Musculoskelet Dis. 2023; 15: 1759720X231158204. https://doi.org/10.1177/1759720X231158204Test.; Roemer F.W., Collins J., Kwoh C.K., et al. MRI based screening for structural definition of eligibility in clinical DMOAD trials: Rapid Osteoarthritis MRI Eligibility Score (ROAMES). Osteoarthritis Cartilage. 2020; 28 (1): 71–81. https://doi.org/10.1016/j.joca.2019.08.005Test.; Brett A., Bowes M.A., Conaghan P.G. Comparison of 3D quantitative osteoarthritis imaging biomarkers from paired CT and MR images: data from the IMI-APPROACH study. BMC Musculoskelet Disord. 2023; 24 (1): 76. https://doi.org/10.1186/s12891-023-06187-2Test.; Kahan A., Uebelhart D., De Vathaire F., et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009; 60 (2): 524–33. https://doi.org/10.1002/art.24255Test.; Vreju F.A., Ciurea P.L., Rosu A., et al. The effect of glucosamine, chondroitin and harpagophytum procumbens on femoral hyaline cartilage thickness in patients with knee osteoarthritis – an MRI versus ultrasonography study. J Mind Med Sci. 2019; 6 (1): 162–8. https://doi.org/10.22543/7674.61.P162168Test.; van der Meijden O.A., Gaskill T.R., Millett P.J. Glenohumeral joint preservation: a review of management options for young, active patients with osteoarthritis. Adv Orthop. 2012; 2012: 160923. https://doi.org/10.1155/2012/160923Test.; Минасов Т.Б., Лила А.М., Назаренко А.Г. и др. Морфологические проявления действия высокоочищенного хондроитина сульфата у пациентов с декомпенсированной формой остеоартрита коленных суставов. Современная ревматология. 2022; 16 (6): 55–63.; Торшин И.Ю., Лила А.М., Наумов А.В. и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (4): 388–99. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066Test.; Li S., Cao P., Chen T., Ding C. Latest insights in disease-modifying osteoarthritis drugs development. Ther Adv Musculoskelet Dis. 2023; 15: 1759720X231169839. https://doi.org/10.1177/1759720X231169839Test.; Громова О.А., Торшин И.Ю., Лила А.М., Громов А.Н. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (2): 38–44. https://doi.org/10.14412/2074-2711-2018-2-38-44Test.; Kim H., Seo J., Lee Y., et al. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities. Ther Adv Musculo-skelet Dis. 2022; 14: 1759720X221085952. https://doi.org/10.1177/1759720X221085952Test.; Jomphe C., Gabriac M., Haleet T.M., et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappa B in interleukin-1 beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008; 102 (1): 59–65. https://doi.org/10.1111/j.1742-7843.2007.00158.xTest.; Шавловская О.А., Громова О.А., Торшин И.Ю. Точки приложения неденатурированного коллагена II типа в терапии скелетно-мышечных болевых синдромов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122 (11): 40–5. https://doi.org/10.17116/jnevro202212211140Test.; Verbruggen G., Goemaere S., Veys E.M. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 1998; Suppl. A: 37–8. https://doi.org/10.1016/s1063-4584Test(98)80010-1.; Yang W., Sun C., He S.Q., et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis – systematic review and network meta-analysis. J Gen Intern Med. 2021; 36 (7): 2085–93. https://doi.org/10.1007/s11606-021-06755-zTest.; Сарвилина И.В., Минасов Т.Б., Лила А.М. и др. Об эффективности парентеральной формы высокоочищенного хондроитина сульфата в режиме периоперационной подготовки к эндопротезированию коленных суставов. Русский медицинский журнал. 2022; 7: 7–16.; Gwinnutt J.M., Wieczorek M., Rodriguez-Carrio J., et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022; 8 (2): e002167. https://doi.org/10.1136/rmdopen-2021-002167Test.; https://www.pharmacoeconomics.ru/jour/article/view/874Test

الإتاحة: https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.207Test
https://doi.org/10.2147/DDDT.S295224Test
https://doi.org/10.1177/1759720X221090297Test
https://doi.org/10.1177/1759720X231165558Test
https://doi.org/10.1016/j.ocarto.2023.100381Test
https://doi.org/10.3390/bioengineering9030099Test
https://doi.org/10.1089/ten.TEC.2020.0309Test
https://doi.org/10.22038/ABJS.2021.56530.2807Test
https://doi.org/10.30802/AALAS-CM-19-000049Test
https://doi.org/10.1097/PHM.0000000000000194Test

المؤلفون: O. A. Shavlovskaya, О. А. Gromova, I. Yu. Torshin, I. D. Romanov, О. А. Шавловская, О. А. Громова, И. Ю. Торшин, И. Д. Романов

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 16, No 2 (2023); 317-330 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 16, No 2 (2023); 317-330 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: глюкозамина сульфат, symptomatic slow acting drugs for osteoarthritis, SYSADOAs, disease-modifying osteoarthritis drugs, DMOADs, chondroitin sulfate, glucosamine sulfate, симптоматические лекарственные средства замедленного действия, СЛСЗД, болезнь-модифицирующие остеоартрит препараты, хондроитина сульфат

وصف الملف: application/pdf

العلاقة: https://www.pharmacoeconomics.ru/jour/article/view/811/479Test; Bruyere O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–50. https://doi.org/10.1016/j.semarthrit.2019.04.008Test.; Bennell K.L., Paterson K.L., Metcalf B.R., et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 2021; 326 (20): 2021–30. https://doi.org/10.1001/jama.2021.19415Test.; Battelli M.G., Polito L., Bortolotti M., Bolognesi A. Xanthine oxidoreductase-derived reactive species: physiological and pathological effects. Oxid Med Cell Longev. 2016; 2016: 3527579. https://doi.org/10.1155/2016/3527579Test.; Jevotovsky D.S., Alfonso A.R., Einhorn T.A., Chiu E.S. Osteoarthritis and stem cell therapy in humans: a systematic review. Osteoarthr Cartil. 2018; 26 (6): 711–29. https://doi.org/10.1016/j.joca.2018.02.906Test.; Druyan M.E., Compher C., Boullata J.I., et al. Clinical guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients: applying the GRADE system to development of A.S.P.E.N. clinical guidelines. JPEN J Parenter Enteral Nutr. 2012; 36 (1): 77–80. https://doi.org/10.1177/0148607111420157Test.; Compher C., Bingham A.L., McCall M., et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: The American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2022; 46 (1): 12–41. https://doi.org/10.1002/jpen.2267Test.; Volpi N. Chondroitin sulfate safety and quality. Molecules. 2019; 24 (8): 1447. https://doi.org/10.3390/molecules24081447Test.; Шавловская О.А. Место препаратов SYSADOA в лечении дегенеративно-дистрофических заболеваний суставов в неврологической практике с позиции доказательной медицины. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122 (3): 38–45. https://doi.org/10.17116/jnevro202212203138Test.; Шавловская О.А., Сарвилина И.В., Громова О.А. и др. Фармакотерапия боли при заболеваниях костно-мышечной системы: эволюция и революция взглядов. Неврология, нейропсихиатрия, психосоматика. 2022; 14 (4): 87–95. https://doi.org/10.14412/2074-2711-2022-4-87-95Test.; Сарвилина И.В., Данилов А.Б. Сравнительный анализ применения симптоматических препаратов замедленного действия, содержащих хондроитина сульфат или влияющих на его биосинтез, у пациентов с неспецифической болью пояснично-крестцовой локализации. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123 (1): 81–96. https://doi.org/10.17116/jnevro202312301181Test.; Лила А.М., Громова О.А., Торшин И.Ю. и др. Молекулярные эффекты Хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (3): 88–97. https://doi.org/10.14412/2074-2711-2017-3-88-97Test.; Торшин И.Ю., Лила А.М., Наумов А.В. и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (4): 388–99. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066Test.; Jordan K.M., Arden N.K., Doherty M., et al. EULAR Recom-mendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62 (12): 1145–55. https://doi.org/10.1136/ard.2003.011742Test.; Volpi N. Condrosulf®: structural characterization, pharmacological activities and mechanism of action. Curr Med Chem. 2014; 21 (34): 3949–61. https://doi.org/10.2174/0929867321666140915142514Test.; Akkoc N., van der Linden S., Khan M.A. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 2006; 20 (3): 539–57. https://doi.org/10.1016/j.berh.2006.03.003Test.; Yang W., Sun C., He S.Q., et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis – systematic review and network meta-analysis. J Gen Intern Med. 2021; 36 (7): 2085–93. https://doi.org/10.1007/s11606-021-06755-zTest.; Gao J., Xia Z., Mary H.B., et al. Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs. Trends Pharmacol Sci. 2022; 43 (3): 171–87. https://doi.org/10.1016/j.tips.2021.12.004Test.; Минасов Т.Б., Лила А.М., Назаренко А.Г. и др. Морфологические проявления действия высокоочищенного хондроитина сульфата у пациентов с декомпенсированной формой остеоартрита коленных суставов. Современная ревматология. 2022; 16 (6): 55–63. https://doi.org/10.14412/1996-7012-2022-6-55-63Test.; Сарвилина И.В., Минасов Т.Б., Лила А.М. и др. Об эффективности парентеральной формы высокоочищенного хондроитина сульфата в режиме периоперационной подготовки к эндопротезированию коленных суставов. РМЖ. 2022; 7: 7–16.; Smolen J.S., Landewe R.B.M., Bijlsma J.W.J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79 (6): 685–99. https://doi.org/10.1136/annrheumdis-2019-216655Test.; Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56 (прил. 1): 1–29. https://doi.org/10.14412/1995-4484-2018-1-29Test.; Розанов А.В., Романов И.Д., Габай П.Г. Медицинские и правовые аспекты соблюдения клинических рекомендаций Минздрава России в амбулаторно-поликлинической практике (интервью с экспертами). РМЖ. 2022; 30 (3): 64–9.; Рубрикатор клинических рекомендаций. Коксартроз. 2021. URL: https://cr.minzdrav.gov.ru/recomend/666_1Test (дата обращения 23.03.2023).; Рубрикатор клинических рекомендаций. Гонартроз. 2021. URL: https://cr.minzdrav.gov.ru/recomend/667_1Test (дата обращения 23.03.2023).; Клинические рекомендации Минздрава России. Падения у пациентов пожилого и старческого возраста. 2020. URL: https://sgp14.ru/allfiles/592f079455623f68e45212941bcff737-1888.pdfTest (дата обращения 23.03.2023).; Клинические рекомендации Минздрава России. Хроническая боль у пациентов пожилого и старческого возраста. 2020. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/118/original/12Test.Хроническая_боль_у_пациентов_пожилого_и_старческого_возраста.pdf?1641888378 (дата обращения 23.03.2023).; Klein R., Becker E.W., Berg P.A., Bernau A. Immunomodulatory properties of rumalon, a glycosaminoglycan peptide complex, in patients with osteoarthritis: activation of T helper cell type 2 cytokines and antigen-specific IgG4 antigen-specific igG4 antibodies. J Rheumatol. 2000; 27 (2): 448–54.; Pavelka K., Gatterova J., Gollerova V., et al. A 5-year randomized controlled, double-blind study of glycosamino glycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000; 8 (5): 335–42. https://doi.org/10.1053/joca.1999.0307Test.; Громова О.А., Торшин И.Ю., Зайчик Б.Ц. и др. О различиях в стандартизации лекарственных препаратов на основе экстрактов хондроитина сульфата. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (1): 50–62. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.083Test.; Bassleer C., Henrotin Y., Franchimont P. In vitro assays of chondrocyte functions: the influence of drugs and hormones. Scand J Rheumatol Suppl. 1990; 81: 13–20. https://doi.org/10.3109/03009749009096940Test.; Mobasheri A., Mahmoudian A., Kalvaityte U., et al. A white paper on collagen hydrolyzates and ultrahydrolyzates: potential supplements to support joint health in osteoarthritis? Curr Rheumatol Rep. 2021; 23 (11): 78. https://doi.org/10.1007/s11926-021-01042-6Test.; WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. URL: https://www.whocc.no/atc_ddd_indexTest/ (дата обращения 23.03.2023).; Венгерович Н.Г., Ефимов Н.В., Рогожина Н.И., Степченков В.И. Подходы к оценке количественного состава лекарственных средств на основе пептидов природного происхождения, содержащих гликозаминогликан-пептидный комплекс. Формулы Фармации. 2020; 2 (1): 8–15. https://doi.org/10.17816/phf20390Test.; Morla S. Glycosaminoglycans and glycosaminoglycan mimetics in cancer and inflammation. Int J Mol Sci. 2019; 20 (8): 1963. https://doi.org/10.3390/ijms20081963Test.; Mohamed H.T., Untereiner V., Sockalingum G.D, Brézillon S. Implementation of infrared and Raman modalities for glycosaminoglycan characterization in complex systems. Glycoconj J. 2017; 34 (3): 309–23. https://doi.org/10.1007/s10719-016-9743-6Test.; Курков А.В., Шехтер А.Б., Пауков В.С. Структурные и функциональные изменения реберных хрящей при воронковидной и килевидной деформации грудной клетки у детей. Архив патологии. 2017; 79 (5): 57–62. https://doi.org/10.17116/patol201779557-62Test.; Erak M., Bellmann-Sickert K., Els-Heindl S., Beck-Sickinger A.G. Peptide chemistry toolbox – transforming natural peptides into peptide therapeutics. Bioorg Med Chem. 2018; 26 (10): 2759–65. https://doi.org/10.1016/j.bmc.2018.01.012Test.; Satake H., Shin Matsubara S., Shiraishi A., et al. Neuropeptides, peptide hormones, and their receptors of a tunicate, ciona intestinalis. Results Probl Cell Differ. 2019; 68: 107–25. https://doi.org/10.1007/978-3-030-23459-1_5Test.; Хавинсон В.Х., Анисимов В.Н. 35-летний опыт исследований пептидной регуляции старения. Успехи геронтологии. 2009; 22 (1): 11–23.; Шавловская О.А., Громова О.А., Торшин И.Ю. Точки приложения неденатурированного коллагена II типа в терапии скелетно-мышечных болевых синдромов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122 (11): 40–5. https://doi.org/10.17116/jnevro202212211140Test.; Elango J., Hou C., Bao B., et al. The molecular interaction of collagen with cell receptors for biological function. Polymers (Basel). 2022; 14 (5): 876. https://doi.org/10.3390/polym14050876Test.; Gencoglu H., Orhan C., Sahin E., Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals (Basel). 2020; 10 (4): 697. https://doi.org/10.3390/ani10040697Test.; Yang Z., Gao X.J., Zhao X. CDMP1 promotes type II collagen and aggrecan synthesis of nucleus pulposus cell via the mediation of ALK6. Eur Rev Med Pharmacol Sci. 2020; 24 (21): 10975–83. https://doi.org/10.26355/eurrev_202011_23581Test.; Yoon H.J., Kim S.B., Somaiya D., et al. Type II collagen and glycosaminoglycan expression induction in primary human chondrocyte by TGF-β1. BMC Musculoskelet Disord. 2015; 16: 141. https://doi.org/10.1186/s12891-015-0599-xTest.; Selistre L., Goncalves G., Vasilceac F. The relationship between urinary C-telopeptide fragments of type II collagen, knee joint load, pain, and physical function in individuals with medial knee osteoarthritis. Braz J Phys Ther. 2021; 25 (1): 62–9. https://doi.org/10.1016/j.bjpt.2020.02.002Test.; Kviatkovsky S.A., Hickner R.C., Ormsbee M.J. Collagen peptide supplementation for pain and function: is it effective? Curr Opin Clin Nutr Metab Care. 2022; 25 (6): 401–6. https://doi.org/10.1097/MCO.0000000000000870Test.; https://www.pharmacoeconomics.ru/jour/article/view/811Test

الإتاحة: https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.183Test
https://doi.org/10.1016/j.semarthrit.2019.04.008Test
https://doi.org/10.1001/jama.2021.19415Test
https://doi.org/10.1155/2016/3527579Test
https://doi.org/10.1016/j.joca.2018.02.906Test
https://doi.org/10.1177/0148607111420157Test
https://doi.org/10.1002/jpen.2267Test
https://doi.org/10.3390/molecules24081447Test
https://doi.org/10.17116/jnevro202212203138Test
https://doi.org/10.14412/2074-2711-2022-4-87-95Test

المؤلفون: Kim, H. (Heungdeok), Seo, J. (Jinwon), Lee, Y. (Yunsin), Park, K. (Kiwon), Perry, T. A. (Thomas A.), Arden, N. K. (Nigel K.), Mobasheri, A. (Ali), Choi, H. (Heonsik)

مصطلحات موضوعية: clinical phenotype, clinical trials, disease-modifying osteoarthritis drugs (DMOADs), drug development, molecular endotype, osteoarthritis (OA)

وصف الملف: application/pdf

الإتاحة: http://urn.fi/urn:nbn:fi-fe2023042839332Test

المؤلفون: Zongmian Song, Yusheng Li, Chunfeng Shang, Guowei Shang, Hongwei Kou, Jinfeng Li, Songfeng Chen, Hongjian Liu

المصدر: Frontiers in Cell and Developmental Biology, Vol 9 (2021)

مصطلحات موضوعية: sprifermin, FGF18, cartilage homeostasis, disease modifying osteoarthritis drugs, osteoarthritis, cartilage-related diseases, Biology (General), QH301-705.5

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fcell.2021.786546/fullTest; https://doaj.org/toc/2296-634XTest

الوصول الحر: https://doaj.org/article/e1d6842aa412475398b636f0755ea266Test

المؤلفون: van Helvoort, E. M., de Visser, H. M., Lafeber, F. P.J.G., Coeleveld, K., Versteeg, S., Weinans, H. H., Popov-Celeketic, J., Eijkelkamp, N., Mastbergen, S. C.

المساهمون: Lab Reumatologie/Klinische Immunologie, Infection & Immunity, Orthopaedie Opleiding, Regenerative Medicine and Stem Cells, ORT Research, CTI Eijkelkamp, Brain, Child Health, Cancer

مصطلحات موضوعية: animal model, chondroprotection, disease-modifying osteoarthritis drugs (DMOAD), osteoarthritis, pain, Immunology and Allergy, Biomedical Engineering, Physical Therapy, Sports Therapy and Rehabilitation

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/443053Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/443053Test

المؤلفون: Franck Brebion (2439052), Romain Gosmini (1738168), Pierre Deprez (1705699), Marie Varin (2479900), Christophe Peixoto (2035117), Luke Alvey (2035129), Hélène Jary (2035114), Natacha Bienvenu (1705657), Nicolas Triballeau (1400671), Roland Blanque (3989681), Céline Cottereaux (9412031), Thierry Christophe (242276), Nele Vandervoort (3989705), Patrick Mollat (206614), Robert Touitou (4376779), Philip Leonard (1621432), Frédéric De Ceuninck (1417306), Iuliana Botez (1701322), Alain Monjardet (3989687), Ellen van der Aar (3989690), David Amantini (232220)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Neuroscience, Physiology, Pharmacology, Biotechnology, Cancer, Science Policy, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, phase 2, knee OA, 1.5 μ M, DMOAD, hydantoin series, Biochemical activity, cocrystal structure, anticatabolic activity, IC 50, glycosaminoglycan release, disease-modifying osteoarthritis, mouse cartilage explants, NCT, GLPG, aggrecanase ADAMTS, HTS, fluorescence-based assay, AGC ELISA

العلاقة: https://figshare.com/articles/journal_contribution/Discovery_of_GLPG1972_S201086_a_Potent_Selective_and_Orally_Bioavailable_ADAMTS_5_Inhibitor_for_the_Treatment_of_Osteoarthritis/14217024Test

الإتاحة: https://doi.org/10.1021/acs.jmedchem.0c02008.s001Test

المؤلفون: Eriko Toyoda, Miki Maehara, Masahiko Watanabe, Masato Sato

المصدر: International Journal of Molecular Sciences; Volume 22; Issue 7; Pages: 3594

مصطلحات موضوعية: disease-modifying osteoarthritis drug, gene therapy, oligonucleotide therapeutics

جغرافية الموضوع: agris

وصف الملف: application/pdf

العلاقة: Molecular Pathology, Diagnostics, and Therapeutics; https://dx.doi.org/10.3390/ijms22073594Test

الإتاحة: https://doi.org/10.3390/ijms22073594Test